3D Systems Corp Signals Turnaround in Earnings Call

3D Systems Corp ((DDD)) has held its Q1 earnings call. Read on for the main highlights of the call.

3D Systems Corp’s latest earnings call struck a cautiously optimistic tone as management detailed a sharp turnaround in revenue and profitability metrics. Executives emphasized broad-based growth across healthcare and industrial markets, stronger margins, and disciplined cost control, while also acknowledging supply chain friction and a deliberately conservative outlook for the next quarter.

Return to Revenue Growth

3D Systems reported first-quarter revenue of $95.5 million, marking an 11% year-over-year increase and a return to clear top-line growth. The rebound was powered by momentum in medical technology, dental applications, and aerospace and defense, signaling renewed demand across its core 3D-printing franchises.

Healthcare Segment Outperformance

Healthcare Solutions emerged as the company’s growth engine, with revenue climbing 21% year-over-year to $50.1 million and becoming the larger segment for the quarter. Management cited robust demand for printers, materials, and medical parts, with titanium spinal and joint implants standing out as key contributors to the segment’s strength.

Aerospace & Defense Momentum

Within Industrial Solutions, aerospace and defense delivered more than 20% year-over-year growth, underscoring rising demand for metal additive manufacturing in mission-critical applications. The company reiterated expectations that its aerospace and defense business could exceed 20% growth in 2026, reaching roughly $35 million in revenue.

Product and Materials Growth

Hardware and consumables both contributed meaningfully, as printers, materials, and parts manufacturing each logged double-digit year-over-year growth. Dental material sales, particularly for aligners and Vertex prosthetic lines, were strong, while metal printer demand increased, including notable traction for the DMP 350 platform.

NextDent 300 Denture Breakthrough

The NextDent 300 jetted denture platform enjoyed a highly successful launch, with customers like ROE Dental Labs reportedly tripling capacity to keep up with demand. Management highlighted recent regulatory approvals in Europe and expected U.S. clearance next year, noting that the addressable market now targets more than 60 million edentulous patients worldwide.

Gross Margin and Cost Savings

Non-GAAP gross margin improved to 36.1%, roughly six percentage points higher than a year ago on an adjusted basis, driven by better factory absorption and a richer mix of consumables. The company said it has already executed more than $55 million in annualized cost savings, helping to expand profitability even as it invests in growth platforms.

Operating Expense Discipline and R&D Shift

Non-GAAP operating expenses fell to $36.6 million, a 35% year-over-year decline when adjusted for divestitures, underscoring a sharp reset in the cost base. Management noted that its recent R&D-intensive product refresh cycle is largely complete and that spending will now migrate toward a more balanced and sustainable R&D profile.

Adjusted EBITDA and EPS Improvement

The company produced positive adjusted EBITDA of $2.1 million in the first quarter, a swing of roughly $26 million versus the prior year, or $28.2 million when adjusted for divestitures. Non-GAAP loss per share narrowed to $0.01 from $0.21, underscoring the earnings leverage created by higher revenue and a leaner operating structure.

Cash Position and Capital Structure

3D Systems ended the quarter with $86.5 million in total cash, including cash and equivalents plus restricted balances, providing a buffer as it navigates macro uncertainty. The firm’s debt profile appears manageable, with only $3.9 million due in late 2026 and the remaining $92 million maturing in 2030, allowing management to prioritize targeted investments over near-term refinancing.

Capacity Expansion and Technology Investment

To support rising demand, the company is adding an 80,000-square-foot expansion at its Littleton facility, scheduled to open later this summer to scale metal parts production for aerospace customers. At the same time, it is advancing a government-supported $28 million development program aimed at next-generation large-format metal printers, deepening its technology moat in industrial additive manufacturing.

Backlog and Raised Production Targets

Management reported a solid order backlog for the denture platform entering the second quarter, reflecting early traction for NextDent 300 in the dental market. On the back of this demand, the company has increased its internal production targets for the second half of the year, betting on continued adoption by large labs and clinical users.

Regional Supply Chain and Logistics Disruptions

Geopolitical tensions in the Middle East weighed on operations, creating supply chain and logistics bottlenecks that slowed deliveries in certain regions. The impact was particularly felt in the jewelry business and contributed to incremental costs, partially muting the benefits of the company’s margin and efficiency gains.

Isolated Customer Disruption

A temporary internal disruption at one key medical customer led to lower-than-expected sales, partly offsetting otherwise solid printer growth in the Med Tech channel. Management characterized the issue as isolated and indicated that it expects sales to this customer to recover as early as the second quarter.

Cautious Near-Term Guidance and Seasonality

For the second quarter, leadership issued cautious guidance, calling for revenue between $93 million and $95 million, roughly flat to slightly below the first quarter. Adjusted EBITDA is projected to swing to a loss of $2 million to $4 million, reflecting typical seasonal softness in healthcare and a careful stance amid macro volatility.

Modest Ongoing Headwinds

The company cautioned that foreign-exchange movements, tariffs, and lingering supply-chain costs continue to weigh modestly on profitability. These pressures, combined with logistical challenges in certain regions, are expected to remain a drag even as internal efficiency programs deliver tangible benefits.

Residual Loss and Execution Risk

Despite the marked improvement, 3D Systems still posted a small non-GAAP net loss per share of $0.01 and warned that quarterly results could remain choppy as it pursues breakeven. Management also acknowledged execution risk stemming from its reliance on a concentrated set of large healthcare, dental, and aerospace customers and the need to maintain manufacturing scale-up amid geopolitical uncertainty.

Forward-Looking Guidance and Strategic Outlook

Looking ahead, the company reaffirmed its full-year goal of achieving breakeven or better on an adjusted EBITDA basis, supported by stable operating expenses and the completion of cost-reduction programs by the end of the second quarter. Management expects aerospace and defense to grow more than 20% in 2026 and sees significant runway in the denture market, where its platform targets over 60 million potential patients, while R&D spending normalizes to support sustained innovation.

3D Systems’ earnings call painted the picture of a company emerging from a restructuring phase with renewed growth and better economics but still facing external and execution risks. For investors, the story now hinges on whether management can convert early wins in healthcare and aerospace into durable cash flow while navigating a deliberately cautious near-term environment.